Search results “Monitoring for lung cancer”
Monitoring for Recurrence in Lung Cancer
Philippa Cheetham, MD; Leora Horn, MD, MSc; and Kim L. Sandler, MD, consider challenges in monitoring patients for disease recurrence and comment on how advances in the field will help experts better manage lung cancer in the near future. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Views: 67 curetoday
EGFR liquid biopsies: a step forward in lung cancer monitoring
A liquid biopsy is a simple, non-invasive alternative to surgical biopsies that enables doctors to use a simple blood sample to discover a range of information about a tumour. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for a specific patient. The test can detect epidermal growth factor receptor (EGFR) gene mutations, which occur in 10-35% of patients with non-small cell lung cancer (NSCLC). To learn more about the role of liquid biopsies in monitoring lung cancer, detecting disease progression and identifying patients likely to respond to tyrosine kinase therapy, visit http://www.roche.com/liquid-biopsy. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 1569 Roche
Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer
Hatim Husain, MD, assistant professor of hematology-oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR mutated NSCLC.
Views: 110 OncLiveTV
Dr. Husain on the Future of Monitoring T790M in Lung Cancer
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).
Views: 213 OncLiveTV
Tumor Markers in Cancer diagnosis and Monitoring
A substance produced by a tumor or by the host in response to the tumor’s presence & can be detected in blood, body fluids or tissue of the host
Views: 6324 Pathology Simplified
Monitoring the Emergence of T790M in EGFR-Mutated Lung Cancer
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of T790M in EGFR-mutated non-small cell lung cancer (NSCLC).
Views: 127 Targeted Oncology
Pioneering Lung Cancer Guide to breathing exercises when in a prone position
This video guide has been developed by physiotherapists to make breathing feel easier. It describes exercises to be conducted when you are lying down. The exercises help you to stretch the sides of your ribcage. We offer the videos as something practical to take away from our Pioneering Lung Cancer site. The complete set of videos are featured on the free Lung+ App, which is available on iTunes and Google Play. http://www.pioneeringhealthcare.com/lung-cancer/living-with-lung-cancer/mobile-app/ More Videos from Roche on http://www.youtube.com/user/roche
Views: 1402 Roche
8-Year-Old Gets Lung Cancer From Chinese Air Pollution
In an official Chinese news report, doctors have diagnosed an 8-year-old girl with lung cancer and attributed the cause to air pollution. The girl, who remained unnamed, is the youngest ever to be diagnosed with lung cancer in China. According to the American Cancer Society, the average age for people acquiring the disease is about 70 years old... Read More At: http://thinkprogress.org/climate/2013/11/05/2890101/air-pollution-8-year-lung-cancer/ Clip from the Tuesday, November 5th 2013 edition of The Kyle Kulinski Show, which airs live on Blog Talk Radio and Secular Talk Radio monday - friday 4-6pm Eastern. Check out our website - and become a member - at: http://www.SecularTalkRadio.com Listen to the Live Show or On Demand archive at: http://www.blogtalkradio.com/kylekulinski Follow on Twitter: http://www.twitter.com/kylekulinski Like on Facebook: http://www.facebook.com/SecularTalk Friends Of SecularTalk: http://www.facebook.com/beastofreason AMAZON LINK: (Bookmark this link to support the show for free!!!) http://www.amazon.com/?tag=seculacom-20
Views: 3100 Secular Talk
Targeted therapies for lung cancer: challenges in side effect management.
Rachel Thomas, lung cancer clinical nurse specialist at Guy's and St Thomas' NHS Foundation Trust, London, UK talks about running a clinic for patients on oral targeted therapies for lung cancer. She explains that monitoring and managing the side effects of treatment are the main challenges, as patients are not always able to recognize and accurately record side effects.
Views: 16 VJOncology
Defining Resectability in Stage IIIA Lung Cancer
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer. http://cancergrace.org/lung/2016/02/09/defining-resectability-in-stage-iii-lung-cancer-really-needs-to-be-under-the-supervision-of-a-qualified-thoracic-surgeon-ultimately-i-say-that-no-one-but-a-surgeon-should-make-the-distinction-of-whe/
SWOG Lung-MAP S1400 Training - Informed Consent, QA and Monitoring
Recording of the S1400 Training Session at the SWOG Spring 2014 Group Meeting. This presentation is by Elaine Armstrong, MS, SWOG Quality Assurance Manager.
Views: 316 SWOGCancerResearch
Lung cancer and precision medicine
Dr Pilar Garrido presents at ecancer's Milan Summit on Precision Medicine 2018 about the current situation regarding lung cancer and precision medicine. She outlines some of the genomic targets for lung cancer, including immunotherapy biomarkers. Dr Garrido also gives her thoughts on the challenges when using NGS. The webcast has been supported by an unrestricted educational grant from Roche Foundation Medicine
Views: 50 ecancer
Keeping Lung Cancer Under Control: Bob's Immunotherapy Story
When Bob was diagnosed with non-small cell lung cancer (NSCLC), his wife Julia was so devastated that she cried for several months thinking about her life without him. Bob weighed all his options with his oncologist. After trying chemotherapy, Bob found another treatment that would give him hope—immunotherapy. He enrolled in a clinical trial of a treatment that helps T-cells to recognize and attack cancer cells. Six years later, Bob's health is stable and he remains optimistic. Bob and Julia urge others to not give up hope because advances in cancer research are rapidly providing new treatment options. Help us continue to bring hope to patients with cancer and support lifesaving (and extending) cancer research: http://bit.ly/MatchCRI
Lung Cancer Screening Program
The Comprehensive Lung Program at Sunrise Hospital & Medical Center’s goal is to diagnose lung cancer in its earliest stage possible. We are committed to educating the community in Las Vegas, Clark County and surrounding communities on the importance of lung cancer screening along with monitoring any incidental findings found on patients imaging studies while a patient at our hospital.
Optimal Specimen Collection for Biomarker Testing in Lung Cancer
Moderated by: Bob McGonnagle, Publisher, CAP TODAY Presenters: Sinchita Roy-Chowdhuri, MD, PhD, and Dara L. Aisner, MD, PhD • Listen to national thought leaders discuss the critical issue of specimen collection • Identify key issues in biomarker testing of specimens in lung cancer • Evaluate the relationship between specimen, test results, and guidelines • Understand the benefits of best practices in precision medicine and pathology For more information: http://www.captodayonline.com Originally broadcast: October 25, 2017 CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a promotional sponsorship from Genentech.
Views: 215 CAP TODAY
Coping with lung cancer recurrence
This video is intended for non-US residents. Connecting with and knowing that other lung cancer patients have experienced recurrence and have been dealing with lung cancer over a period of time can be very helpful. Consider joining a lung cancer patient support group. For more information on lung cancer and lung cancer treatments, visit: http://www.lifewithlungcancer.info
Views: 236 LifeWithLungCancer
Lung cancer: benefits of liquid biopsy
Gustave Roussy presents at ASCO 2017 two studies showing the advantages of liquid biopsy (blood test) to detect genetic mutations in tumoral cells’ DNA in order to target the treatment and to monitor the disease. Prof. Benjamin Besse (Gustave Roussy, France) explanations.
Views: 205 Gustave Roussy
Liquid biopsy in lung cancer: state of the art and future applications-  A.Marchetti
Genomics in Oncology lecture series invites Antonio Marchetti, Professor of Pathology and Director of the Center of Predictive Molecular Medicine at the University of Chieti in Italy. Professor Marchetti presents his research with liquid biopsies in lung cancer and shares his perspective on the future of applying next-generation sequencing technology in plasma to drive the future of personalized medicine. Learn more about Genomics in Oncology, visit our website: http://www.illumina.com/areas-of-interest/cancer/research.html A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM
Views: 971 Illumina Inc
Catching and treating lung cancer early with electromagnetic navigation bronchoscopy
Electromagnetic navigation bronchoscopy (ENB) is helping doctors detect and treat lung cancer in its initial stages. Onalee is now cancer free after four years of monitoring the nodule on her lung that ended up being stage 1 lung cancer. Early intervention makes a big difference in saving lives. According to the American Cancer Society, about 160,000 Americans die of lung cancer every year, making up more than 1/4 of all cancer-related deaths.
Views: 311 Borgess Health
Monitoring, managing, and mitigating immune-related adverse events
In this presentation from the 22nd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses monitoring, managing, and mitigating immune-related adverse events (Aes) in the treatment of lung cancer. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=lung © 2017 Imedex, LLC.
Views: 95 ImedexCME
Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.
Views: 79 VJOncology
Emerging Biomarkers in Lung Cancer
Philip C. Mack, PhD, discusses emerging biomarkers in lung cancer and the potential for technological advances to improve outcomes.
Views: 216 OncLiveTV
Precision Medicine in Oncology: Monitoring Cancer Using a Urine Sample | Antonius Schuch | TEDxUCSD
Antonius Schuch challenges and shows us how precise analytical techniques can help us address the needs of healthcare and improve the quality of life. Antonius Schuh joined Trovagene as Chief Executive Officer in October 2011 and was elected as a Director in December 2011. He is a certified pharmacist and earned his PhD in pharmaceutical chemistry from the University of Bonn, Germany. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 1918 TEDx Talks
Dispelling Myths Surrounding Lung Cancer
Dr. Leora Horn and Chris Draft remark on types of risk factors, aside from smoking, that potentially play a role in lung cancer, and remark on considerations for connecting patients to appropriate healthcare professionals when monitoring and managing the disease. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Views: 19 curetoday
The role of the blood-brain barrier in lung cancer treatment
Some types of cancer, such as anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), frequently spread into the brain and central nervous system. A key challenge in treating these brain metastases is the blood-brain barrier, which guards the brain against the entry of certain molecules. Learn why crossing the blood-brain barrier is important in overcoming certain cancers. To learn how to overcome the blood-brain barrier, visit http://www.roche.com/brain_shuttle. For more information on lung cancer, visit http://www.roche.com/lung-cancer. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 11438 Roche
New Drug for Lung Cancer
It's being hailed as a breakthrough medicine; a twice-daily pill that targets the growth of a specific type of lung cancer. The FDA fast-tracked its approval. "I think it was very exciting because it's sort of a proof that these targeted therapies for cancers can be affective," says Dr. Lowell Hart, a hematologist/oncologist on the medical staff of Lee Memorial Health System. Dr. Lowell Hart has three patients on the drug, now named Xalkori. He saw the drug make a dramatic impact. "It was very impressive to me that these were sick patients who had had their cancer progress through chemotherapy no longer working on chemo, so we would expect them to not do very well and perhaps not live very long but have had very dramatic responses to the drug," says Dr. Hart. The drug only works on the 5-10% of lung cancers which have a specific gene knows as ALK. Many people with it are non-smokers who developed 'small lung cancer'. "All three of my patients that have this mutation are women and non-smokers," says Dr. Hart. The new drug blocks protein produced by the ALK gene. It's a targeted therapy, which researchers believe is the future of controlling or curing cancer. The FDA also approved a screening test. "I am personally checking everybody and I think you know my partners are in general checking everybody and the tests are now commercially available," says Dr. Hart. Xalkori comes with a high price tag, upwards of $100,000 a year, on par with traditional chemo. Drug maker Pfizer is expected to work with insurance companies to limit out of pocket expenses, important in making the drug available to those who need it. "I've seen that very few times in my career of over 25 years. I said this drug is the real thing," says Dr. Hart. View More Health Matters video segments at leememorial.org/​healthmatters/​ Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries. Visit leememorial.org
Views: 952 Lee Health
Will Lung Cancer Treatment Affect Other Organs?
Dr. Hanson explains that chemotherapy treatment for lung cancer can often affect other organs, such as the blood organ, bone marrow, and nerves. Patients that undergo treatment through radiation can also expect that organs hit by the radiation could suffer damage. David S. Hanson, MD, FACP: Oftentimes patients under treatment for lung cancer are concerned about the effects their therapy may have on their body and this is entirely appropriate. Patients who receive chemotherapy for lung cancer can expect that there may damage done to other organs. The most common is the blood organ or the bone marrow and that is because the chemotherapy arrest the growth of those cells, which may cause anemia, which is a low grade blood count and can cause weakness and fatigue or low white cell counts, which can predispose a person to infection or low platelet counts, which may predispose to bleeding. For that reason, during the course of treatment, your doctor will be monitoring your blood counts and likely adjusting your chemotherapy should there be major abnormalities that develop. There are other organs that are also at risk for damage during lung cancer treatment. The most common concern are the nerves. The common chemotherapy that works very well for lung cancer can cause numbness and tingling to come in the hands and feet, that this does not occur for all patients but you and your physician will be monitoring carefully for this and probably make adjustments in your treatment should such damage occur. Many times, if that damage is detected early it can be reversed. There are other organs that are at risk for damage from chemotherapy, which include the liver and the kidneys. The doctor will obtain blood test generally to determine whether or not these organs are functioning normally and if they are not, make adjustments in your treatment. The important thing to know is that you and your doctor will be working as a team to look at the side effects of your treatment and make plans about modifying your treatment to respect those side effects that develop. Finally, there are times when patients must have radiation treatment as a part of their lung cancer treatment plan and radiation can do damage to the organs at which it is end. For that reason your radiation oncologist will make a very careful treatment plan, talk with you about what tissues might be at risk for damage and list out for you those things that you and he or she can do to manage those side effects. Commonly, there may be a skin burn that is apparent on the skin and the area that is given radiation. Proper treatment of the skin can control the symptoms from that irritation and make it far less of a difficult thing to manage than if its not attended too properly. David S. Hanson, MD practices oncology and internal medicine in Baton Rouge and Zachary, Louisiana. Dr. Hanson graduated with an MD 27 years ago. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Views: 6320 Best Doctors
Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer. http://cancergrace.org/lung/2016/01/27/gcvl_lu_serum_tumor_markers_lung_cancer_management/
Radon Decay Product causes lung cancer
http://www.nationalradondefense.com | 1-888-370-6921 This informational video explains how radon travels into building and decays into radioactive particles. These radioactive particles are called Radon Decay Products, or Radon Progeny. These particles can get inhaled into our lungs and cause lung cancer.
TKIs in Squamous Non-Small Cell Lung Cancer: LUX-Lung-8
The panelists, Benjamin Levy, MD; Edward S. Kim, MD, FACP; and Paul K. Paik, MD, discuss the role of tyrosine kinase inhibitors in the treatment of squamous non-small cell lung cancer.
Views: 210 OncLiveTV
What Is A Calcified Granuloma In The Lung?
Granuloma what does it mean? Mayo clinic. Experts consider it to be singularly unhelpful for monitoring a new lung cancer calcified granuloma is mass within the tissues of particular organ, usually lungs, which has. It scared me to death when my doctor sent the last catscan showed a punctate calcified granuloma. They can become calcified over time, as calcium tends to answer (1 of 5) a granuloma is not sign lung cancer more often than they do require any major treatment. I have a spot on my lung the size of quarter. Granuloma what does it mean? Mayo clinic mayoclinic granuloma expert answers faq 20057838 url? Q webcache. Although granulomas due to histoplasmosis are noncancerous (benign), they may resemble cancer on an x ray, especially if haven't calcified. (2014) calcified granulomatous lung lesions contain abundant mycobacterium tuberculosis may 29, 2003 hi im new. Often, a granuloma becomes calcified, citation iida t, uchida k, lokman n, furukawa a, suzuki y, et al. Calcified granuloma in chest x ray, could it be lung cancer? (very calcified lower lobe of right inspiregrace global resource for what is a granuloma? (with pictures). Granulomas eventually become calcified and have the same density as bone, making them more clearly visible on an x ray jan 20, 2011 has done wonderful not had anymore trouble. Googleusercontent search. The cause of inflammation can be fungal, bacterial or parasitic, jun 16, 2012 well, the doctor called me back and said x ray was 'normal,' but that i had a calcified granuloma should get another chest in radiologist noted there 'calcified bottom lobe my right lung. Calcification of the granuloma causes differential considerations a calcified lesion include granuloma, hamartoma, carcinoid, osteosarcoma, chondrosarcoma and lung metastases or because it usually takes some time for calcium to be deposited in is generally assumed that an old area inflammation. Just recently had chest x ray and ct scan show calcified granuloma in lungs liver is normally seen the rarely kidneys or other organs of body. Pulmonary nodules (lung nodules) is calcified granuloma in the lung some form of cancer? Is it a lungs & calcium granulomatous lesions contain abundant granuloma? Possibly cancer? Lung respiratory. The calcified lung nodule what does it mean? Ncbi nih. I went in the er with flu and pneumonia. For example, a calcified granuloma in the lung may be due to tuberculosis contracted years earlier that is now inactive and dormant most common cause of nodule calcification formation, usually response ground glass nodulesby location[ ] show little or no growth for 2 yearscentral granulomas cancer are by far two causes pulmonary sep 16, 2011 nodules caused inflammation. Ask an expert calcified granulomata in lungs netwellness. Medical definition of calcified granuloma medicinenetradiology reference article chest radiology university virginia. What is a lung granuloma? Cancerconnect. Calcification refers to the accumulation of calcium most
Views: 3023 Another Question
Lung Cancer Screening Overdiagnosis
Dr. Ned Patz discusses his latest study analyzing the rate of over diagnosis in the National Lung Screening Trial for lung cancer screening with low dose CT.
Views: 224 Duke Radiology
CNS Metastasis in ALK positive lung cancer
Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses the question of central nervous system (CNS) metastasis in patients with ALK positive tumors. CNS metastasis is a big issue in when treating ALK-positive tumors. Approximately 30% of patients show CNS metastasis even before they are treated with an ALK inhibitors, but after first treatment with an ALK inhibitor, 60-70% show CNS metastasis. Dr Griesinger explains that having targeted drugs that effectively target the CNS metastases would allow to delay whole-brain irradiation, thus delaying the associated cognitive impairment experienced by patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Views: 177 VJOncology
Strand Life Sciences launches ‘STRAND LB’ - a ground-breaking method for monitoring cancer

Strand Life Sciences launches ‘STRAND LB’ - a ground-breaking method for monitoring cancer Strand LB helps monitor lung, breast, colorectal and other cancers for tumor presence, response, and recurrence Bangalore, April 11th 2017: According to data from the Indian Council of Medical Research (ICMR), India is projected to have 17.3 lakhs new cases of cancer reported in 2020 and over 8.8 lakhs patients are expected to die from the disease. To counter this large burden and rapid increase in incidence and persistence of the high mortality rate of 50%, there is a strong need for better ways to diagnose, manage, and treat cancer. Strand Life Sciences today announced the launch of their Liquid Biopsy test portfolio ‘STRAND LB’ that provides highly sensitive detection of tumor traces from a simple blood draw. This powerful tool can provide early and precise indication of tumor presence, cancer recurrence, and response to therapy compared to any other method used in the medical industry. Typically, tumors are assessed through invasive tumor biopsies or through radioactive scans. This latest technique allows earlier assessment with minimal discomfort to patients. “Liquid biopsy is a paradigm shift that involves a minimally-invasive procedure, no radioactive scans, and can detect tumor DNA traces from a simple blood draw. However, detecting tumor DNA requires a highly sensitive test capable of detecting 1 molecule in a 1000. Our study on patients spanning a wide variety of cancer types – including lung, colorectal, breast, and bladder cancer - shows that STRAND LB can detect tumor DNA traces in as many as 35% of patients with early-stage cancer, going up to 70-90% in patients with locally advanced or metastatic cancer. These figures are at par with the best in the world”, said Dr. Vijay Chandru, Chairman and Managing Director, Strand Life Sciences. The Strand LB tests are an outcome of the collaboration between Scientific teams of Strand and Mazumdar Shaw Center for Translational Research (MSCTR), who worked together to develop these advanced tests which were validated by clinicians at the Mazumdar Shaw Medical Center (MSMC). These non-invasive Liquid Biopsy tests will advance the field of cancer diagnostics, as they offer ultra-sensitive detection of mutations which will help in early detection and intervention. To reflect the collaboration these tests will be made available and offered to all patients at MSMC. “Innovations like Liquid Biopsy are huge breakthroughs in cancer detection and management. India needs such pioneering innovation in healthcare to foster early detection which can be a great help in bringing down the non-communicable disease (NCD) burden that our country is facing today. I congratulate the scientific teams at Strand and MSCTR as well as doctors at MSMC
Lung cancer results from any abnormality in the basic unit of life — the cell. Generally, our bodies have the ability to check various activities and growth patterns of cells. Cancer occurs when this system is damaged. This causes an abnormal growth pattern in the cells of the body which, in turn, leads to a tumor. 1. Carboplatin This drug was on the market in the late 1980’s and has very few side effects when compared to other drugs in the same group. It is used for the treatment of ovarian carcinoma and lung, head, and neck cancers. Side effects, including damage to the kidney, nausea, etc., are within controllable levels. 2. Cisplatin This is a platinum-based drug used to cure the cancers of sarcomas, small cell lung cancer, ovarian cancer, lymphomas, and germ cell tumors. The drug was the first member of the class of platinum based chemotherapy drugs. It acts by causing apoptosis of cells. Its side effects are more severe compared to other drugs and include nephrotoxicity or kidney damage, neurotoxicity or nerve damage, ototoxicity or hearing loss, and nausea and vomiting. 3. Docetaxel This drug is well researched and established for anti-mitotic chemotherapy and marketed under the brand name Taxotere. Used mainly for the treatment of non-small cell lung cancer, breast, and ovarian cancer, docetaxel has FDA approval for use in relapsed cancer cases. It is considered to be a more effective drug than doxorubicin, fluorouracil, and paclitaxel. It is used in cancer treatment in cases where anthracycline-based chemotherapy has failed. 4. Etoposide This cancer drug is marketed under the brand names Eposin, Vepesid, VP-16, and Etopophos. It inhibits an enzyme release necessary for DNA functioning. Cancer cells are less competent in repairing this damage as compared to normal cells. It is used mainly for treating Ewing's sarcoma, lymphoma, non-lymphocytic leukemia, lung cancer, glioblastoma multiforme, and testicular cancer. 5. Gemcitabine It is marked under the brand name Gemzar and is a nucleoside analog. The drug is used for various types of cancer viz. non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer. It is being researched for use in esophageal cancers and various other tumor types and lymphomas. The common side effects of the drug include muscle pain, fever, headache, chills, fatigue, mild nausea, and vomiting. Article Credit: http://www.newsmax.com/FastFeatures/lung-cancer-drugs-treatment/2011/01/28/id/369824/ Subscribe: https://www.youtube.com/channel/UCkVKbsi4wOka3tK0IWPFKRA/videos
Views: 69 Disease Fact
Saving Lives with Lung Cancer Screening
At Roswell Park, our High Risk Lung Cancer Screening Program is designed to detect lung cancer at its earliest, most curable stages by screening and monitoring the people most likely to develop the disease, especially smokers. Learn more at http://www.roswellpark.org/highrisklung.
Views: 66 RPCICancerTalk
Part 1 of 2, Isodose Based Methodology, Lung Cancer Radiosurgery Planning Example
Walkthrough of a lung radiosurgery case using the isodose based methodology to minimize the morbidity and mortality of treatment. Narrated by Hiram Gay, radiation oncologist, and Karen Fish, medical dosimetrist. This video is intended for instructional purposes only. Always use the most recent and validated dose volume contraints, treatment techniques and dose prescriptions in the literature. Based on the journal article: Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. Published in Radiotherapy & Oncology and authored by Hiram A. Gay, Claudio H. Sibata, Ron R. Allison, and Branislav Jeremic. PMID: 19058867
Views: 6129 hiramag
What is the Utility of Serum Tumor Markers in Lung Cancer?
Dr. Jack West, medical oncologist at the Swedish Cancer Institute in Seattle, Washington, discusses the controversial topic of whether or how to use serum tumor markers to guide clinical decisions for patients with lung cancer, and explains what serum tumor markers are. For more information about lung cancer, visit http://www.swedish.org/lungcancer.
Views: 737 swedishseattle
EGFR Testing for NSCLC
Panelists Mark Socinski, MD; Vali Papadimitrakopoulou, MD; Tracey Evans, MD; Alexander Drilon, MD; and Jared Weiss, MD, provide insight on which EGFR mutations to test for in patients with non–small cell lung cancer.
Views: 1449 OncLiveTV
Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer
Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib (Alecensa) as first-line therapy in the treatment of patients with lung cancer. Though crizotinib (Xalkori) is currently the standard first-line therapy in lung cancer, the J-ALEX study reported out of Japan showed positive results in the alectinib population, suggesting that alectinib may be more effective than crizotinib first-line. According to Shaw, there is more movement toward using alectinib as the preferred second-generation, second-line ALK inhibitor due to its efficacy and side effect profile. There was a response rate of 50% in crizotinib-resistant patients, an immediate progression-free survival of about 9 months, striking CNS activity, and very manageable side effects of fatigue, edema and muscle aches at grades 1/2. Currently, there is a global ALEX study that addresses some of the problems of the original study, such as limited ethnicity range.
Views: 826 OncLiveTV
NCLEX Medical Surgical Nursing Exam for Lung Cancer | NCLEXExam.NET
This 27 Questions and answer NCLEX Medical Surgical Nursing Exam for Lung Cancer | NCLEXExam.NET In Video Mode: All questions and answers are given for listening and answering at your. ======================================================= Here are link full DVD for "Gas Exchange and Respiratory Management | NCLEX med surg nursing Exam": - NCLEX Practice Exam for Respiratory System 1: https://youtu.be/pN6E1frtemo - NCLEX Practice Exam for Respiratory System 2: https://youtu.be/cYtWdWRerzk - NCLEX Practice Exam for Respiratory System 3: https://youtu.be/EF7Ha6WLVaE - NCLEX Medical-Surgical Nursing Exam for Acute Respiratory Distress Syndrome: https://youtu.be/Cn3CA1sv9O4 _ NCLEX Medical-Surgical Nursing Exam for Asthma and COPD: https://youtu.be/fPJ5muXPsyQ _ NCLEX Medical-Surgical Nursing Exam for Asthma: https://youtu.be/rPo3YMna1lA _ NCLEX Medical-Surgical Nursing Exam for Bronchitis (Acute & Chronic): https://youtu.be/lOX_bxfnRv0 _ NCLEX Medical-Surgical Nursing Exam for COPD: https://youtu.be/XOFaS3Y_TBg _ NCLEX Medical-Surgical Nursing Exam for Cystic Fibrosis: https://youtu.be/VxefWzK8pEw _ NCLEX Medical-Surgical Nursing Exam for Emphysema: https://youtu.be/y9RNYD9FHQk _ NCLEX Medical-Surgical Nursing Exam for Lung Cancer: https://youtu.be/v5uvq-3wOHA _ NCLEX Medical-Surgical Nursing Exam for Pneumonia and Tuberculosis: https://youtu.be/D9X4HWd2Oes _ NCLEX Medical-Surgical Nursing Exam for Pneumonia: https://youtu.be/0sTImAVFnMc _ NCLEX Medical-Surgical Nursing Exam for Pneumothorax: https://youtu.be/ulBtDAOkOv0 _ NCLEX Medical-Surgical Nursing Exam for Respiratory System: https://youtu.be/3Js_kaQ555o ====================================================== Please subscribe to update new videos!!!
Lung Cancer Video Library - PDL1 As A Biomarker For First Line
We are pleased to have GRACE's Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute in Seattle, Washington, and President and CEO of GRACE bring 2017 updates to our Lung Cancer Video Library. In this latest video, Dr. West discusses exciting new advances in NSCLC - PDL1 as a Biomarker for First Line. http://cancerGRACE.org/
A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the use of pembrolizumab monotherapy in the first-line setting, referencing KEYNOTE-024 data (NCT02142738). Prof. Reck then goes on to discuss the next steps for investigating pembrolizumab combination therapy, such as that being explored in the Phase III KEYNOTE-189 trial (NCT02578680). This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Views: 31 VJOncology